PulseAugur
EN
LIVE 22:37:38
中文(ZH) “星锐医药”完成近4000万美元B+轮融资

Starry Pharma raises $40M for cell therapy, Uncharted Dynamics secures seed funding

By PulseAugur Editorial · [1 sources] ·

Starry Pharma has secured nearly $40 million in Series B+ funding, with participation from investors including Hillhouse Ventures, LYFE Capital, and Lilly Asia Ventures. The capital will accelerate clinical development for its in vivo CAR-T therapies and expand its mRNA innovation efforts. Separately, Uncharted Dynamics, a company focused on embodied AI infrastructure, raised a seed round of several million dollars led by Summit Ascent, to fund R&D for its high-precision dynamics solver and North American expansion. AI

IMPACT These funding rounds will advance AI infrastructure and therapeutic development, potentially accelerating innovation in embodied AI and cell-based treatments.

RANK_REASON The cluster contains two distinct funding rounds for AI-related companies, one of which is a significant amount for a Series B+ round. [lever_c_demoted from significant: ic=1 ai=0.7]

Read on 36氪 (36Kr) →

AI-generated summary · Google Gemini · from 1 sources. How we write summaries →

Starry Pharma raises $40M for cell therapy, Uncharted Dynamics secures seed funding

How we ranked this

Signal score
0 / 100
Composite score across the factors below. Higher = stronger signal that this story matters right now.
Newsworthiness bucket
Research
The cluster contains two distinct funding rounds for AI-related companies, one of which is a significant amount for a Series B+ round. [lever_c_demoted from significant: ic=1 ai=0.7]
Source corroboration
Single-source cluster
Only one publisher covered this so far. Single-source stories can still rank when the publisher is high-authority, but they lack cross-source corroboration.
Topics
funding, product
Editorial topic classification. Feeds into how the story surfaces on /topic/<slug> hub pages and into the per-entity coverage mix.
AI-industry relevance
High
Clearly on-topic for AI-industry coverage.
Story freshness
138 days old
Aged out of breaking-news scoring windows; ranking reflects the durable signal from the full source set.

Full methodology in our editorial standards.

COVERAGE [1]

  1. 36氪 (36Kr) TIER_1 中文(ZH) ·

    Star-Sharp Pharma Completes Nearly $40 Million Series B+ Financing

    36氪获悉，“星锐医药”宣布完成近4000万美元B+轮融资。本轮融资由产业基金联合高瓴创投、LYFE Capital (洲嶺资本）、礼来亚洲基金（LAV)、夏尔巴投资、源码资本及春华资本共同参投。本次募集资金将重点用于加速体内细胞治疗（in vivo CAR-T） 多条管线的临床开发进程、推进肺部、肠道及神经系统等肝外递送平台的搭建，巩固并强化公司在mRNA治疗领域的创新研发布局。

RELATED TOPICS